How The Narrative Around Nektar Therapeutics (NKTR) Is Shifting With Rezpeg Data And Litigation Risks [Yahoo! Finance]
Nektar Therapeutics (NKTR)
Last nektar therapeutics earnings: 2/27 04:15 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.nektar.com/investor-relations
Company Research
Source: Yahoo! Finance
revenue growth assumption for Rezpeg edged to a 10.83% decline. This reflects a slightly less negative view of future sales potential tied to upcoming clinical data and Alopecia Areata optionality. Behind that small shift is a tug of war in Street research between bullish views that Rezpeg's clinical profile could support higher long term revenue and cautious voices that point to low success odds, model volatility, and unresolved Lilly litigation. Stay tuned to see how you can keep up with these moving assumptions and what they might mean for Nektar's evolving stock narrative. Stay updated as the Fair Value for Nektar Therapeutics shifts by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on Nektar Therapeutics. ?? Bullish Takeaways Jefferies recently lifted its Nektar price target to US$121 from US$99, reflecting a view that current expectations around Rezpeg look relatively low compared with what they see as the drug'
Show less
Read more
Impact Snapshot
Event Time:
NKTR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NKTR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NKTR alerts
High impacting Nektar Therapeutics news events
Weekly update
A roundup of the hottest topics
NKTR
News
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTRPR Newswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTRGlobeNewswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTRPR Newswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTRGlobeNewswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTRPR Newswire
NKTR
Earnings
- 11/6/25 - Beat
NKTR
Sec Filings
- 12/23/25 - Form 4
- 12/23/25 - Form 4
- 12/16/25 - Form 8-K
- NKTR's page on the SEC website